Stay updated on Pembrolizumab and TKI in CML MRD Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and TKI in CML MRD Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2. Removed the government funding operating status notice and Revision: v3.4.1.
    Difference
    0.1%
    Check dated 2026-02-11T02:39:50.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a site-wide notice about a lapse in government funding and updated the revision from v3.4.0 to v3.4.1.
    Difference
    0.1%
    Check dated 2026-02-03T23:53:27.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a Show glossary option and updated revision metadata (Last Update Posted 2026-01-23, Last Update that Met QC Criteria 2026-01-26) to revision v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-27T21:51:19.000Z thumbnail image
  5. Check
    49 days ago
    Change Detected
    Summary
    Recent changes are administrative updates to the study record dates (December 2025 and November 2025). They do not modify core study information such as eligibility, interventions, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-06T16:39:14.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Locations section added and lists study sites by state (Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Idaho, Illinois, Iowa, Kansas, Kentucky, Maryland, Michigan, Minnesota, Missouri, Montana, Nebraska, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, Washington, West Virginia, Wisconsin, Wyoming) with Revision: v3.3.3. Per-state location subsections were removed, the HHS Vulnerability Disclosure link was removed, and the revision updated from v3.3.2.
    Difference
    1.0%
    Check dated 2025-12-23T08:38:24.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    The page shows a new Revision: v3.3.2 added and a Revision: v3.3.1 removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T16:42:39.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and TKI in CML MRD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.